Abstract | BACKGROUND AND OBJECTIVES: EVIDENCE AND INFORMATION SOURCES: Low molecular weight heparins (LMWHs) are produced by the depolymerization of UFH. LMWHs have pharmacologic advantages over UFH: a better bioavailability after subcutaneous administration, a longer plasma half-life and a more predictable anticoagulant effect. These improved features allow once or twice daily subcutaneous injection of weight-adjusted doses of LMWHs without requiring laboratory monitoring in patients with VTE or unstable angina. PERSPECTIVES:
|
Authors | Giancarlo Agnelli, Francesco Sonaglia |
Journal | Haematologica
(Haematologica)
Vol. 87
Issue 7
Pg. 757-70
(Jul 2002)
ISSN: 0390-6078 [Print] Italy |
PMID | 12091128
(Publication Type: Journal Article, Review)
|
Chemical References |
- Blood Coagulation Factors
- Fibrinolytic Agents
- Heparin, Low-Molecular-Weight
- Serine Proteinase Inhibitors
- Heparin
|
Topics |
- Blood Coagulation Factors
(antagonists & inhibitors)
- Fibrinolytic Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Heparin
(adverse effects, pharmacokinetics, therapeutic use)
- Heparin, Low-Molecular-Weight
(adverse effects, pharmacokinetics, therapeutic use)
- Humans
- Postoperative Complications
(drug therapy, prevention & control)
- Serine Proteinase Inhibitors
(pharmacokinetics, therapeutic use)
- Thrombosis
(drug therapy, prevention & control)
|